Studies show that patients taking GLP-1 medications often experience systolic and diastolic blood pressure improvements alongside weight loss, suggesting a connection between the medication class and heart health outcomes
Clinical guidelines continue to reflect this nuance
Eseonu D, Su T, Lee K, Chumpitazi BP, Shulman RJ, Hernaez R
How the Study Was Conducted The experiment involved 36 male Sprague Dawley rats divided into four experimental groups: Control (C): Healthy animals receiving no active treatment Streptozotocin (STZ): Animals with induced diabetes but no medication STZ + Retatrutide (STZR): Animals with induced diabetes treated with retatrutide Retatrutide (R): Healthy animals treated with retatrutide Animals in the treatment groups received a daily subcutaneous dose of 0.015 mg/kg of retatrutide for 21 consecutive days
As we age, natural GH production declines significantly
More recently, I started using L-Carnitine again this November (2015)